Prelude Capital Management, LLC Exact Sciences Corp Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$56.27 - $73.77 $802,466 - $1.05 Million
14,261 New
14,261 $984,000
Q3 2023

Nov 14, 2023
BUY
$65.94 - $99.04 $272,398 - $409,134
4,131 New
4,131 $281,000
Q4 2022

Feb 14, 2023
BUY
$30.35 - $53.15 $238,095 - $416,961
7,845 New
7,845 $388,000
Q4 2021

Feb 14, 2022
SELL
$72.5 - $100.68 $160,225 - $222,502
-2,210 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$90.24 - $124.05 $199,430 - $274,150
2,210 New
2,210 $211,000
Q4 2020

Feb 16, 2021
SELL
$99.61 - $142.12 $48,808 - $69,638
-490 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$72.92 - $102.01 $35,730 - $49,984
490 New
490 $50,000
Q2 2020

Aug 14, 2020
SELL
$55.75 - $92.75 $375,922 - $625,413
-6,743 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$37.9 - $104.44 $198,596 - $547,265
5,240 Added 348.64%
6,743 $391,000
Q4 2019

Feb 14, 2020
BUY
$77.66 - $99.74 $116,722 - $149,909
1,503 New
1,503 $139,000
Q3 2018

Nov 14, 2018
SELL
$48.29 - $80.6 $1.65 Million - $2.75 Million
-34,115 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$37.84 - $69.96 $1.23 Million - $2.27 Million
32,396 Added 1884.58%
34,115 $2.04 Million
Q1 2018

May 15, 2018
BUY
$39.82 - $57.53 $68,450 - $98,894
1,719 New
1,719 $69,000

Others Institutions Holding EXAS

# of Institutions
673
Shares Held
162M
Call Options Held
2.58M
Put Options Held
2.19M
View Full List

About EXACT SCIENCES CORP

EXAS Quotes by TradingView
  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email